Kristine Ashcraft is a molecular biologist by training and is CEO of YouScript Inc. She has worked in precision medicine since 2000 and was recently named one of the 25 leading global voices in the space. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at a recent AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at PMWC, SXSW, ASHG, and numerous Precision Medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.
YouScript’s personalized medication management technology synthesizes all evidence impacting drug response to support doctors and pharmacists in making faster, more proactive decisions at the point of care. Clinically validated and successfully implemented in major health systems, we’re on a mission to be a trusted partner in eliminating avoidable adverse drug events.
Maximizing the Clinical And Financial Benefits Of Pharmacogenetics With Integrated CDST
Systems implementing precision medicine programs have warned that EHR-integrated CDST needs to be a priority. See the added value that YouScript has provided in impacting clinical decisions and reducing ED visits, hospitalizations, readmissions, and costs. In addition to peer-reviewed studies, we will cover recent real-world validations including a Highmark BCBS VITAL innovation program at an Allegheny Health Network clinic and a large-scale longitudinal claims analysis completed by a major U.S. payer.